MEN1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita (now Ryvu Therapeutics) and acquired by the Menarini Group at the beginning of 2017.
The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).
None of the molecules currently in clinical development has this dual activity.
The multicenter, Phase I/II clinical trial DIAMOND-01 is currently ongoing in patients with relapsed /refractory AML.
VISIT OUR CLINICAL TRIALS DATABASE